3/18/2020

Grünenthal considers the outbreak and spread of Covid-19 (known as new coronavirus) to be a serious situation and fully recognises its responsibilities related to safeguarding the well-being and safety of our employees, ensuring an uninterrupted supply of our medicines for patients, and supporting communities with curbing the Covid-19 outbreak.

11/29/2019

Zur Zeit wird in den Medien berichtet, dass die Conterganstiftung beabsichtigt, die Zahlungen an brasilianische Betroffene, die durch das Produkt "Sedalis" geschädigt wurden, einzustellen. Wir nehmen wie folgt Stellung:

11/29/2019

We have recorded numerous media reports about the intent of the German Contergan Foundation to cease payments to people affected by "Sedalis". Grünenthal's position on this matter is as follows:

7/1/2019

Grünenthal decided to discontinue its two ongoing Phase III clinical trials of Neridronate (KF7013-02 and KF7013-04) in patients with Complex Regional Pain Syndrome (CRPS). The clinical development program had foreseen to randomize 360 people with CRPS in these trials.